查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2000605

生技藥品契約製造市場：2026年至2032年全球市場預測（依分子類型、生產流程、生產規模、技術平台、治療領域及最終用戶分類）

Biologics Contract Manufacturing Market by Molecule Type, Process Step, Production Scale, Technology Platform, Therapeutic Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生技藥品契約製造市場價值將達到 310.4 億美元，到 2026 年將成長至 363.1 億美元，到 2032 年將達到 950 億美元，複合年成長率為 17.32%。

主要市場統計數據
基準年 2025 310.4億美元
預計年份：2026年 363.1億美元
預測年份 2032 950億美元
複合年成長率 (%) 17.32%

簡要概述科學突破和營運需求如何改變生物製藥契約製造的策略和執行。

生物製藥契約製造產業處於科學創新、嚴格監管和工業規模生產的交匯點。過去十年，細胞和基因治療、單株抗體、重組蛋白和疫苗研發的進步改變了人們對速度、柔軟性和產品特定製程設計的期望。因此，契約製造生產商必須在複雜的科學工作流程和工業限制之間取得平衡，同時確保不同客戶專案的品質一致性和合規性。

技術進步、治療方法多樣化和供應鏈演變如何協同改變生物製藥生產實踐和夥伴關係模式。

生物製藥契約製造的格局正在經歷一場變革，其驅動力包括技術成熟、治療產品線的變化以及整個供應鏈風險認知的轉變。細胞和基因療法等先進治療方法催生了高度個人化的產品形式，需要客製化的製程開發、密封系統和嚴格的低溫運輸物流。同時，單株抗體和重組蛋白仍需要高通量、穩健的生產平台，這些平台優先考慮下游製程的產量最佳化和純度。

評估美國關稅調整對生物製藥生產原料對營運和供應鏈以及戰略採購決策的影響。

鑑於預計2025年關稅政策和貿易政策將發生變化，各公司正在重新評估籌資策略、供應商選擇以及生產和採購基地的地域多元化。進口一次性零件、特殊不銹鋼配件和生物程序耗材的關稅增加，可能會導致投入成本上升，並擠壓利潤空間，除非製造商和贊助商採取相應的抵消措施。

詳細的細分分析揭示分子類型、製程步驟、生產規模、技術平台、治療領域、最終用戶和製造模式如何影響能力要求。

一個穩健的細分框架能夠明確哪些領域需要根據客戶需求量身定做的能力，以及哪些領域能夠帶來最大的投資回報。從分子類型（例如細胞療法、基因療法、單株抗體、重組蛋白和疫苗）的角度分析細分，可以發現製程要求差異顯著。細胞和基因平台需要封閉式系統和專門的病毒載體處理，而單株抗體則專注於高效價上游工程和深度下游純化。

全球市場的區域趨勢及其對產能分配、監管合作和跨境製造夥伴關係的戰略意義。

區域趨勢持續影響契約製造製造商和申辦者在考慮產能分配和監管合作時的策略重點。在美洲，健全的生物技術生態系統和完善的法規結構正推動私人投資，用於快速臨床應用和模組化生產能力；同時，該地區成熟的供應鏈也為藥物研發和商業化生產領域的強大外包合作關係提供了支持。

供應商如何透過技術專業化、整合分析、策略合作和靈活的製造地部署來滿足贊助商的各種需求，從而實現差異化。

領先的契約製造製造商和服務供應商正透過平台專業化、整合服務交付以及投資拓展技術深度和地理覆蓋範圍來提升自身競爭力。一些公司專注於先進治療方法，例如病毒載體生產和封閉式細胞療法工藝，而另一些公司則在擴大抗體和重組蛋白的生產規模，以滿足大規模商業項目的需求。在整個產業中，分析測試專業知識已成為一項重要的競爭優勢，各公司紛紛採用高通量特性、功效檢測和先進的生物分析技術來縮短產品上市週期並支援複雜的對比測試方案。

為增強韌性、最佳化營運以及使生產能力藍圖與新治療方法和監管要求保持一致提供切實可行的建議。

產業領導企業應採取果斷行動，增強韌性，提高成本效益，並從不斷變化的治療趨勢中創造價值。首先，各組織應優先考慮設施設計的模組化，並檢驗一次性使用和不銹鋼工藝線的互通性，以保持宣傳活動的靈活性並縮短換線時間。同時，投資強大的分析測試平台和可擴展的下游生產能力，將有助於進行更有效率的對比試驗，並縮短複雜生物製藥產品的上市週期。

透過結合對從業人員的訪談、監管分析、採購模式和技術文獻，我們透過高度透明和基於三角測量的調查方法，產生實用見解。

本分析整合了從行業相關人員訪談、技術白皮書、監管指南更新以及公開策略文件中獲得的定性和定量資訊。調查方法強調三角驗證，將營運、品質和商業部門高階領導的第一手資料與技術文獻和產品平臺資訊披露進行比較，以檢驗營運影響和新興趨勢。此外，還調查了設備採購模式、專利活動和已報告的產能擴張情況，以推斷平台採用和地理部署的變化。

關於協調產能投資、供應鏈韌性和夥伴關係模式以確保複雜生物製藥可靠交付的結論

生物製藥契約製造產業正處於關鍵時刻，需要整合科學創新和營運策略才能確保專案成功。細胞和基因療法的進步，以及對單株抗體和重組蛋白的持續需求，都要求製造商具備先進的技術能力和靈活的營運能力。供應鏈壓力和政策變化凸顯了採購多元化和區域韌性的重要性，而諸如採用一次性系統還是不銹鋼系統等技術選擇，則需要根據專案的風險狀況和加工能力需求進行仔細權衡。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按分子類型分類的生技藥品契約製造市場

  • 細胞療法
  • 基因治療
  • 單株抗體
  • 重組蛋白
  • 疫苗

第9章：生技藥品契約製造市場（依工藝分類）

  • 分析測試
  • 下游
  • 填充和精加工
  • 配方
  • 上游

第10章：依生產規模分類的生技藥品契約製造市場

  • 商業的
  • 第一階段
  • 第二階段
  • 第三階段
  • 臨床前

第11章：按技術平台分類的生技藥品契約製造市場

  • 免洗系統
  • 不銹鋼系統

第12章：生技藥品契約製造市場：依治療領域分類

  • 自體免疫疾病
  • 感染疾病
  • 腫瘤學
  • 罕見疾病

第13章：生技藥品契約製造市場：依最終用戶分類

  • 生技公司
  • 合約服務供應商
  • 製藥公司
  • 研究機構

第14章：生技藥品契約製造市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：生技藥品契約製造市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：生技藥品契約製造市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國生技藥品契約製造市場

第18章：中國生技藥品契約製造市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie, Inc.
  • Abzena Ltd.
  • Acino International AG
  • ADMA Biologics, Inc.
  • AGC Biologics
  • Ajinomoto Bio-Pharma Services
  • Avid Bioservices, Inc.
  • Baxter International, Inc
  • Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • FUJIFILM Diosynth Biotechnologies USA, Inc. by FUJIFILM Corporation
  • JSR Life Sciences, LLC by JSR Group
  • Kemwell Biopharma Pvt. Ltd.
  • Lonza Group Ltd.
  • Midas Pharma GmbH
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co. Ltd.
  • Wacker Chemie AG
  • WuXi Biologics Co., Ltd.
Product Code: MRR-8C74ADFBFD4E

The Biologics Contract Manufacturing Market was valued at USD 31.04 billion in 2025 and is projected to grow to USD 36.31 billion in 2026, with a CAGR of 17.32%, reaching USD 95.00 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 31.04 billion
Estimated Year [2026] USD 36.31 billion
Forecast Year [2032] USD 95.00 billion
CAGR (%) 17.32%

A concise overview of how scientific breakthroughs and operational demands are reshaping biologics contract manufacturing strategy and execution

The biologics contract manufacturing sector operates at the confluence of scientific innovation, regulatory rigor, and industrial-scale production. Over the last decade, advances in cell and gene therapies, monoclonal antibodies, recombinant proteins, and vaccine development have shifted expectations for speed, flexibility, and product-specific process design. As a result, contract manufacturers must reconcile complex scientific workflows with industrial constraints while ensuring consistent quality and regulatory compliance across diverse customer programs.

More specifically, firms increasingly confront the need to provide integrated services that span upstream development through fill-finish and analytical testing, while accommodating varied production scales from preclinical runs to full commercial manufacture. This evolving requirement has amplified the importance of modular facility design and cross-functional project management capabilities. Moreover, technology choices between single-use systems and traditional stainless steel platforms now require strategic evaluation against long-term operational costs, contamination risk profiles, and campaign flexibility.

Consequently, companies that align technical expertise with responsive supply chain management and a clear regulatory strategy will gain a decisive advantage. This report examines those dynamics and provides the context necessary for executives to align investments, partnerships, and capacity planning with the scientific and commercial realities that define successful biologics manufacturing engagements.

How technological advances, therapeutic diversification, and supply chain evolution are jointly transforming biologics manufacturing practices and partnership models

The landscape of biologics contract manufacturing is undergoing transformative shifts driven by technological maturation, changing therapeutic pipelines, and evolving risk perceptions across supply chains. Advanced therapies such as cell and gene modalities have introduced highly personalized product formats that require bespoke process development, closed-system handling, and stringent cold-chain logistics. At the same time, monoclonal antibodies and recombinant proteins continue to demand high-throughput, robust manufacturing platforms that emphasize yield optimization and downstream purity.

Transitioning to single-use technologies has accelerated flexibility and reduced turnaround for multi-campaign facilities, yet it has also shifted procurement emphasis toward validated suppliers and disposable component supply security. In parallel, fill-finish operations have attracted renewed focus as final product integrity and packaging complexities increase with parenteral biologics and combination products. Regulatory regimes are adapting, with greater scrutiny on comparability, viral safety, and data integrity, thereby raising the bar for analytical testing capabilities.

As a result, manufacturing models are fragmenting: some sponsors favor dedicated facilities for strategic control, whereas others opt for fee-for-service or virtual manufacturing arrangements to preserve capital and speed development. The cumulative effect encourages contract manufacturers to offer platform-based solutions, invest in adaptable process trains, and strengthen partnerships across the value chain to remain competitive and resilient.

Assessing the operational and supply chain consequences of the United States tariff adjustments for biologics manufacturing inputs and strategic sourcing decisions

Anticipated tariff changes and trade policy adjustments announced for 2025 are prompting companies to reassess procurement strategies, supplier selection, and geographic distribution of manufacturing and sourcing. Tariff-driven increases on imported single-use components, specialized stainless steel fittings, and bioprocess consumables can elevate input costs and compress margins unless manufacturers and sponsors implement compensatory measures.

In response, many organizations are accelerating supplier qualification programs, diversifying approved vendor lists, and exploring nearshoring or reshoring alternatives to mitigate exposure to cross-border duties. These shifts are prompting capital deployment into regional supply chains and domestic manufacturing capacity, especially for high-value or mission-critical inputs. Additionally, procurement teams are renegotiating long-term agreements and developing hedging strategies where feasible to stabilize cost trajectories.

Consequently, tariff pressures also influence site selection decisions for new facilities, encourage investment in alternative technologies that reduce reliance on tariffed imports, and increase collaboration between sponsors and contract manufacturers to share risk. While tariffs present headwinds, they simultaneously create an impetus for localized resilience, supplier development, and strategic contract structures that protect program timelines and product quality.

Detailed segmentation analysis revealing how molecule types, process steps, production scales, technology platforms, therapeutic focuses, end users, and manufacturing models drive capability requirements

A robust segmentation framework clarifies where capabilities must align with customer needs and where investments will yield the greatest operational return. When segmentation is viewed through the lens of molecule types such as cell therapy, gene therapy, monoclonal antibody, recombinant protein, and vaccine, it becomes clear that process requirements diverge significantly: cell and gene platforms need closed systems and specialized viral vector processing, while monoclonal antibodies emphasize high-titer upstream processes and intensive downstream purification.

Similarly, dissecting the value chain by process steps-analytical testing, downstream, fill-finish, formulation, and upstream-reveals discrete skill sets, equipment footprints, and regulatory demands that must be coordinated across project timelines. Production scale segmentation from preclinical through Phase I, Phase II, Phase III, to commercial introduces cadence and capacity planning challenges, as scale-up pathways differ materially between platform technologies and molecule classes.

Technology platform choices between single-use systems and stainless steel systems also shape facility layout, changeover time, and validation strategies. Therapeutic areas such as autoimmune, infectious disease, oncology, and rare disease drive different risk tolerances and program velocities that affect prioritization. End users including biotechnology companies, contract service providers, pharmaceutical companies, and research institutes require tailored engagement models and service level agreements. Finally, manufacturing models-dedicated facility, fee-for-service, multiproduct facility, and virtual manufacturing-determine capital intensity, margin structure, and commercial flexibility. Together, these segmentation lenses inform capability roadmaps and help executives prioritize investments that align operational design with client needs.

Regional dynamics and strategic implications for capacity allocation, regulatory engagement, and cross-border manufacturing partnerships across global markets

Regional dynamics continue to shape strategic priorities for contract manufacturers and sponsors as they assess capacity allocation and regulatory engagement. In the Americas, strong biotech ecosystems and well-established regulatory frameworks favor rapid clinical translation and private investment into modular manufacturing capacity, while the region's mature supply chains support robust outsourcing partnerships for both discovery-stage work and commercial production.

In contrast, Europe, Middle East & Africa present a heterogeneous landscape where high regulatory standards coexist with varying national incentives for biomanufacturing investment. Several European markets emphasize advanced therapeutics and have strong academic-industry linkages that support translational pipelines, whereas regional policy initiatives in parts of the Middle East and Africa aim to bootstrap local capabilities through targeted incentives and public-private partnerships.

Asia-Pacific has emerged as a focal point for capacity expansion, driven by large-scale pharmaceutical manufacturing experience, growing domestic biotech sectors, and government-backed initiatives to secure manufacturing sovereignty. Across all regions, cross-border collaboration persists, but decision-makers are increasingly factoring geopolitical risk, trade policy, and regional logistics resilience into site selection and supplier qualification decisions. These regional nuances influence where companies place development activities, which partners they select, and how they sequence global production networks to balance speed, cost, and regulatory access.

How providers are differentiating through technical specialization, integrated analytics, strategic alliances, and flexible manufacturing footprints to meet diverse sponsor needs

Leading contract manufacturers and service providers are differentiating through platform specialization, integrated service offerings, and investments that expand both technical depth and geographic reach. Some firms concentrate on advanced therapy capabilities such as viral vector production and closed-system cell therapy processes, while others build scale in antibody and recombinant protein production to serve large-volume commercial programs. Across the sector, analytical testing proficiency has become a competitive differentiator, with companies adding high-throughput characterization, potency assays, and advanced bioanalytics to shorten release cycles and support complex comparability packages.

Partnership models also vary: strategic alliances with component suppliers ensure continuity of single-use materials, whereas joint ventures with regional players facilitate faster market entry and localized supply. Meanwhile, firms that adopt flexible manufacturing systems and invest in automation see improvements in campaign efficiency and data integrity, while those that prioritize regulatory engagement and quality systems reduce approval risks and accelerate tech transfers. Ultimately, competitive positioning derives from the ability to combine technical excellence with service orchestration, enabling clients to move programs from early development into commercial supply without fragmentation or unnecessary delay.

Actionable recommendations for strengthening resilience, optimizing operations, and aligning manufacturing capability roadmaps with emerging therapeutic and regulatory demands

Industry leaders should take decisive actions to strengthen resilience, improve cost-efficiency, and capture value from evolving therapeutic trends. First, organizations should prioritize modularity in facility design and validate the interoperability of single-use and stainless steel process trains to maintain campaign agility and reduce changeover time. Concurrently, investing in robust analytical testing platforms and scalable downstream capabilities will streamline comparability demonstrations and reduce release timelines for complex biologics.

Second, companies must diversify supplier portfolios for critical disposables and raw materials, accelerate supplier qualification, and pursue regional sourcing strategies where feasible to mitigate tariff and trade risks. In addition, operational leaders should formalize technology roadmaps that include increased automation, digital batch records, and process analytical technology to enhance reproducibility and regulatory readiness. Third, firms should evaluate hybrid manufacturing models that blend dedicated capacity for strategic programs with multiproduct and fee-for-service offerings to optimize utilization and preserve client confidentiality.

Finally, strengthening collaborative partnerships with sponsors, academic centers, and regional stakeholders will accelerate talent development and regulatory alignment. Implementing these recommendations will better position organizations to respond to therapeutic innovation, policy shifts, and supply chain perturbations while maintaining high standards of product quality and program continuity.

Transparent and triangulated research methodology combining practitioner interviews, regulatory analysis, procurement patterns, and technical literature to produce actionable insights

This analysis synthesizes qualitative and quantitative inputs drawn from industry interviews, technical white papers, regulatory guidance updates, and publicly reported strategic filings. The methodology emphasizes triangulation: primary insights from senior operations, quality, and commercial leaders were cross-referenced against technical literature and product pipeline disclosures to validate operational implications and emergent trends. Equipment procurement patterns, patent activity, and reported capacity expansions were examined to infer directional shifts in platform adoption and geographic deployment.

Data integrity was reinforced through validation of regulatory notifications and inspection outcomes, which helped surface areas of recurring compliance focus and accelerated the identification of critical capability gaps in viral safety, sterility assurance, and analytical breadth. Where appropriate, anonymized case studies from recent tech transfers were used to illustrate practical constraints and successful mitigation strategies. While proprietary quantitative projections were not included in this narrative, the methodology supports transparency by documenting sources, interview protocols, and criteria used for technology and supplier assessment.

Collectively, this approach balances practitioner experience with documentary evidence to produce actionable, defensible insights for executives making capital, sourcing, and partnership decisions in the biologics contract manufacturing space.

Concluding perspectives on aligning capability investment, supply chain resilience, and partnership models to reliably deliver complex biologic therapies

The biologics contract manufacturing sector stands at a pivotal moment where scientific innovation and operational strategy must converge to sustain program success. Advances in cell and gene therapies, alongside enduring demand for monoclonal antibodies and recombinant proteins, require manufacturers to be both technically deep and operationally nimble. Supply chain pressures and policy shifts highlight the importance of diversified sourcing and regional resilience, while technology choices around single-use versus stainless steel systems demand careful alignment with program risk profiles and throughput needs.

Executives who integrate robust analytical capabilities, modular facility design, and strategic supplier relationships will be better positioned to translate innovation into reliable supply. Moreover, adopting flexible commercial models that balance dedicated capacity with multiproduct offerings enables firms to serve diverse client needs without sacrificing quality or speed. As the industry evolves, leaders must synchronize investment priorities with therapeutic trends and regulatory expectations to maintain competitiveness and ensure patient access to complex biologic therapies.

In short, the path forward requires deliberate engineering of capabilities, proactive risk management, and collaborative partnerships that together deliver the operational reliability necessary for modern biologics development and commercialization.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Contract Manufacturing Market, by Molecule Type

  • 8.1. Cell Therapy
  • 8.2. Gene Therapy
  • 8.3. Monoclonal Antibody
  • 8.4. Recombinant Protein
  • 8.5. Vaccine

9. Biologics Contract Manufacturing Market, by Process Step

  • 9.1. Analytical Testing
  • 9.2. Downstream
  • 9.3. Fill Finish
  • 9.4. Formulation
  • 9.5. Upstream

10. Biologics Contract Manufacturing Market, by Production Scale

  • 10.1. Commercial
  • 10.2. Phase I
  • 10.3. Phase II
  • 10.4. Phase III
  • 10.5. Preclinical

11. Biologics Contract Manufacturing Market, by Technology Platform

  • 11.1. Single Use System
  • 11.2. Stainless Steel System

12. Biologics Contract Manufacturing Market, by Therapeutic Area

  • 12.1. Autoimmune
  • 12.2. Infectious Disease
  • 12.3. Oncology
  • 12.4. Rare Disease

13. Biologics Contract Manufacturing Market, by End User

  • 13.1. Biotechnology Company
  • 13.2. Contract Service Provider
  • 13.3. Pharmaceutical Company
  • 13.4. Research Institute

14. Biologics Contract Manufacturing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Biologics Contract Manufacturing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Biologics Contract Manufacturing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Biologics Contract Manufacturing Market

18. China Biologics Contract Manufacturing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie, Inc.
  • 19.6. Abzena Ltd.
  • 19.7. Acino International AG
  • 19.8. ADMA Biologics, Inc.
  • 19.9. AGC Biologics
  • 19.10. Ajinomoto Bio-Pharma Services
  • 19.11. Avid Bioservices, Inc.
  • 19.12. Baxter International, Inc
  • 19.13. Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
  • 19.14. Cambrex Corporation
  • 19.15. Catalent, Inc.
  • 19.16. Emergent BioSolutions, Inc.
  • 19.17. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
  • 19.18. JSR Life Sciences, LLC by JSR Group
  • 19.19. Kemwell Biopharma Pvt. Ltd.
  • 19.20. Lonza Group Ltd.
  • 19.21. Midas Pharma GmbH
  • 19.22. ProBioGen AG
  • 19.23. Recipharm AB
  • 19.24. Rentschler Biopharma SE
  • 19.25. Samsung Biologics
  • 19.26. Thermo Fisher Scientific, Inc.
  • 19.27. Toyobo Co. Ltd.
  • 19.28. Wacker Chemie AG
  • 19.29. WuXi Biologics Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 151. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 153. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 154. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 172. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 173. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 174. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 175. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 179. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 181. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 182. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)